Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.micpath.2021.104929 http://scihub22266oqcxt.onion/10.1016/j.micpath.2021.104929 33932547!8081582!33932547     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Microb+Pathog 2021 ; 156 (ä): 104929 Nephropedia Template TP {{tp|p=33932547|t=2021. Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro |pdf=|usr=}}{{33932547}} gab.com Text Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro JO: Microb Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33932547 #FOAvip Since the beginning of December 2019, a novel Coronavirus severe respiratory disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which also been termed 2019-new CoV (2019-nCoV), has continued to spread worldwide. As of August 27, 2020, a total of 24,232,429 people have been infected and 826,518 people have died. In our study, we found that astemizole can antagonize ACE2 and inhibit the entry of SARS-COV-2 spike pseudovirus into ACE2-expressed HEK293T cells (ACE2hi cells). We analysied the binding character of astemizole to ACE2 by molecular docking and surface plasmon resonance (SPR) assays and molecule docking, SARS-COV-2 spike pseudotype virus was also taken to investigate the suppression viropexis effect of astemizole. The results showed that astemizole can bind to the ACE2 receptor and inhibit the invasion of SARS-COV-2 Spike pseudoviruses. Thus astemizole represent potential drug candidates that can be re-used in anti-coronavirus therapies. Twit Text FOAVip Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro ????Microb Pathog http://www.kidney.de/pget.php?&tw=1&pmid=33932547 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33932547 #FOAvip English Wikipedia <ref>{{Cite pmid|33932547}}</ref> Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro #MMPMID33932547 Wang X; Lu J; Ge S; Hou Y; Hu T; Lv Y; Wang C; He H Microb Pathog 2021[Jul]; 156 (ä): 104929 PMID33932547show ga Since the beginning of December 2019, a novel Coronavirus severe respiratory disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which also been termed 2019-new CoV (2019-nCoV), has continued to spread worldwide. As of August 27, 2020, a total of 24,232,429 people have been infected and 826,518 people have died. In our study, we found that astemizole can antagonize ACE2 and inhibit the entry of SARS-COV-2 spike pseudovirus into ACE2-expressed HEK293T cells (ACE2hi cells). We analysied the binding character of astemizole to ACE2 by molecular docking and surface plasmon resonance (SPR) assays and molecule docking, SARS-COV-2 spike pseudotype virus was also taken to investigate the suppression viropexis effect of astemizole. The results showed that astemizole can bind to the ACE2 receptor and inhibit the invasion of SARS-COV-2 Spike pseudoviruses. Thus astemizole represent potential drug candidates that can be re-used in anti-coronavirus therapies. |*COVID-19[MESH] |*Pharmaceutical Preparations[MESH] |Astemizole/pharmacology[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Protein Binding[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus[MESH]Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro (epmc).pdf DeepDyve Pubget Overpricing